HALEON PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 334.4 GBX | +0.87% |
|
+4.11% | +3.96% |
| Apr. 25 | Moody’s Affirms Haleon’s Ratings on Strong Operating Performance | MT |
| Apr. 24 | Haleon: a new CFO at the end of October | CF |
Presenter SpeechSonya Ghobrial (Executives)Good morning, good afternoon, everyone. Thank you f...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows:
- oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.;
- Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.;
- medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.;
- respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.;
- vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.344
GBP
Average target price
3.594
GBP
Spread / Average Target
+7.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.96% | 37.83B | |
| +25.83% | 653B | |
| +27.00% | 556B | |
| -6.76% | 354B | |
| +20.34% | 331B | |
| +3.00% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.26% | 144B |
- Stock Market
- Equities
- HLN Stock
- News Haleon plc
- Transcript : Haleon plc, H1 2022 Earnings Call, Sep 20, 2022
